Merck
CN
  • Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.

Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.

Bioorganic & medicinal chemistry (2013-03-07)
Martine Keenan, Paul W Alexander, Hugo Diao, Wayne M Best, Andrea Khong, Maria Kerfoot, R C Andrew Thompson, Karen L White, David M Shackleford, Eileen Ryan, Alison D Gregg, Susan A Charman, Thomas W von Geldern, Ivan Scandale, Eric Chatelain
摘要

A scaffold hopping exercise undertaken to expand the structural diversity of the fenarimol series of anti-Trypanosoma cruzi (T. cruzi) compounds led to preparation of simple 1-[phenyl(pyridin-3-yl)methyl]piperazinyl analogues of fenarimol which were investigated for their ability to inhibit T. cruzi in vitro in a whole organism assay. A range of compounds bearing amide, sulfonamide, carbamate/carbonate and aryl moieties exhibited low nM activities and two analogues were further studied for in vivo efficacy in a mouse model of T. cruzi infection. One compound, the citrate salt of 37, was efficacious in a mouse model of acute T. cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days.

材料
货号
品牌
产品描述

Sigma-Aldrich
哌嗪, ReagentPlus®, 99%
Sigma-Aldrich
哌嗪, BioUltra, anhydrous, ≥99.0% (T)
Supelco
哌嗪 六水合物, analytical standard
Supelco
氯苯嘧啶醇, PESTANAL®, analytical standard